Candidate anti-Aβ fluorene compounds selected from analogs of amyloid imaging agents

Hyun Seok Hong, Izumi Maezawa, Madhu Budamagunta, Sandeep Rana, Aibin Shi, Robert Vassar, Ruiwu Liu, Kit Lam, R. Holland Cheng, Duy H. Hua, John C Voss, Lee-Way Jin

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is characterized by depositions of β-amyloid (Aβ) aggregates as amyloid in the brain. To facilitate diagnosis of AD by radioligand imaging, several highly specific small-molecule amyloid ligands have been developed. Because amyloid ligands display excellent pharmacokinetics properties and brain bioavailability, and because we have previously shown that some amyloid ligands bind the highly neurotoxic Aβ oligomers (AβO) with high affinities, they may also be valuable candidates for anti-Aβ therapies. Here we identified two fluorene compounds from libraries of amyloid ligands, initially based on their ability to block cell death secondary to intracellular AβO. We found that the lead fluorenes were able to reduce the amyloid burden including the levels of AβO in cultured neurons and in 5xFAD mice. To explain these in vitro and in vivo effects, we found that the lead fluorenes bind and destabilize AβO as shown by electron paramagnetic resonance spectroscopy studies, and block the harmful AβO-synapse interaction. These fluorenes and future derivatives, therefore, have a potential use in AD therapy and research.

Original languageEnglish (US)
Pages (from-to)1690-1699
Number of pages10
JournalNeurobiology of Aging
Volume31
Issue number10
DOIs
StatePublished - Oct 2010

Fingerprint

Amyloid
Fluorenes
Ligands
Alzheimer Disease
Aptitude
Electron Spin Resonance Spectroscopy
Brain
fluorene
Synapses
Biological Availability
Spectrum Analysis
Cell Death
Pharmacokinetics
Neurons
Therapeutics
Research

Keywords

  • Alzheimer's disease
  • Amyloid ligand
  • Amyloid-β
  • Electron paramagnetic resonance spectroscopy
  • Oligomer
  • Small molecules
  • Spin-label
  • Synapse

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Aging
  • Developmental Biology
  • Geriatrics and Gerontology

Cite this

Candidate anti-Aβ fluorene compounds selected from analogs of amyloid imaging agents. / Hong, Hyun Seok; Maezawa, Izumi; Budamagunta, Madhu; Rana, Sandeep; Shi, Aibin; Vassar, Robert; Liu, Ruiwu; Lam, Kit; Cheng, R. Holland; Hua, Duy H.; Voss, John C; Jin, Lee-Way.

In: Neurobiology of Aging, Vol. 31, No. 10, 10.2010, p. 1690-1699.

Research output: Contribution to journalArticle

Hong, Hyun Seok ; Maezawa, Izumi ; Budamagunta, Madhu ; Rana, Sandeep ; Shi, Aibin ; Vassar, Robert ; Liu, Ruiwu ; Lam, Kit ; Cheng, R. Holland ; Hua, Duy H. ; Voss, John C ; Jin, Lee-Way. / Candidate anti-Aβ fluorene compounds selected from analogs of amyloid imaging agents. In: Neurobiology of Aging. 2010 ; Vol. 31, No. 10. pp. 1690-1699.
@article{d9845b0a651e4c93a0c48a93a3fdcfee,
title = "Candidate anti-Aβ fluorene compounds selected from analogs of amyloid imaging agents",
abstract = "Alzheimer's disease (AD) is characterized by depositions of β-amyloid (Aβ) aggregates as amyloid in the brain. To facilitate diagnosis of AD by radioligand imaging, several highly specific small-molecule amyloid ligands have been developed. Because amyloid ligands display excellent pharmacokinetics properties and brain bioavailability, and because we have previously shown that some amyloid ligands bind the highly neurotoxic Aβ oligomers (AβO) with high affinities, they may also be valuable candidates for anti-Aβ therapies. Here we identified two fluorene compounds from libraries of amyloid ligands, initially based on their ability to block cell death secondary to intracellular AβO. We found that the lead fluorenes were able to reduce the amyloid burden including the levels of AβO in cultured neurons and in 5xFAD mice. To explain these in vitro and in vivo effects, we found that the lead fluorenes bind and destabilize AβO as shown by electron paramagnetic resonance spectroscopy studies, and block the harmful AβO-synapse interaction. These fluorenes and future derivatives, therefore, have a potential use in AD therapy and research.",
keywords = "Alzheimer's disease, Amyloid ligand, Amyloid-β, Electron paramagnetic resonance spectroscopy, Oligomer, Small molecules, Spin-label, Synapse",
author = "Hong, {Hyun Seok} and Izumi Maezawa and Madhu Budamagunta and Sandeep Rana and Aibin Shi and Robert Vassar and Ruiwu Liu and Kit Lam and Cheng, {R. Holland} and Hua, {Duy H.} and Voss, {John C} and Lee-Way Jin",
year = "2010",
month = "10",
doi = "10.1016/j.neurobiolaging.2008.09.019",
language = "English (US)",
volume = "31",
pages = "1690--1699",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Candidate anti-Aβ fluorene compounds selected from analogs of amyloid imaging agents

AU - Hong, Hyun Seok

AU - Maezawa, Izumi

AU - Budamagunta, Madhu

AU - Rana, Sandeep

AU - Shi, Aibin

AU - Vassar, Robert

AU - Liu, Ruiwu

AU - Lam, Kit

AU - Cheng, R. Holland

AU - Hua, Duy H.

AU - Voss, John C

AU - Jin, Lee-Way

PY - 2010/10

Y1 - 2010/10

N2 - Alzheimer's disease (AD) is characterized by depositions of β-amyloid (Aβ) aggregates as amyloid in the brain. To facilitate diagnosis of AD by radioligand imaging, several highly specific small-molecule amyloid ligands have been developed. Because amyloid ligands display excellent pharmacokinetics properties and brain bioavailability, and because we have previously shown that some amyloid ligands bind the highly neurotoxic Aβ oligomers (AβO) with high affinities, they may also be valuable candidates for anti-Aβ therapies. Here we identified two fluorene compounds from libraries of amyloid ligands, initially based on their ability to block cell death secondary to intracellular AβO. We found that the lead fluorenes were able to reduce the amyloid burden including the levels of AβO in cultured neurons and in 5xFAD mice. To explain these in vitro and in vivo effects, we found that the lead fluorenes bind and destabilize AβO as shown by electron paramagnetic resonance spectroscopy studies, and block the harmful AβO-synapse interaction. These fluorenes and future derivatives, therefore, have a potential use in AD therapy and research.

AB - Alzheimer's disease (AD) is characterized by depositions of β-amyloid (Aβ) aggregates as amyloid in the brain. To facilitate diagnosis of AD by radioligand imaging, several highly specific small-molecule amyloid ligands have been developed. Because amyloid ligands display excellent pharmacokinetics properties and brain bioavailability, and because we have previously shown that some amyloid ligands bind the highly neurotoxic Aβ oligomers (AβO) with high affinities, they may also be valuable candidates for anti-Aβ therapies. Here we identified two fluorene compounds from libraries of amyloid ligands, initially based on their ability to block cell death secondary to intracellular AβO. We found that the lead fluorenes were able to reduce the amyloid burden including the levels of AβO in cultured neurons and in 5xFAD mice. To explain these in vitro and in vivo effects, we found that the lead fluorenes bind and destabilize AβO as shown by electron paramagnetic resonance spectroscopy studies, and block the harmful AβO-synapse interaction. These fluorenes and future derivatives, therefore, have a potential use in AD therapy and research.

KW - Alzheimer's disease

KW - Amyloid ligand

KW - Amyloid-β

KW - Electron paramagnetic resonance spectroscopy

KW - Oligomer

KW - Small molecules

KW - Spin-label

KW - Synapse

UR - http://www.scopus.com/inward/record.url?scp=77955841406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955841406&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2008.09.019

DO - 10.1016/j.neurobiolaging.2008.09.019

M3 - Article

C2 - 19022536

AN - SCOPUS:77955841406

VL - 31

SP - 1690

EP - 1699

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

IS - 10

ER -